Cell Medica Collaborator, Baylor College of Medicine, Showcasing Promise of CAR-NKT Therapies at American Society of Gene & Cell Therapy 22nd Annual Meeting

  • Collaboration with Baylor College of Medicine and Texas Children's Hospital includes ground-breaking GINAKIT2 Phase 1 trial
  • GINAKIT2 is evaluating highly innovative CAR therapy utilizing natural killer T cell (CAR-NKT) therapy, CMD-501, in children with relapsed or refractory (R/R) high risk neuroblastoma
  • Collaboration is also developing off-the-shelf CAR-NKT products for hematological and solid tumors

HOUSTON & LONDON--(BUSINESS WIRE)-- Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, announced today that its collaborators from Baylor College of Medicine and Texas Children's Hospital will be presenting the latest progress related to its innovative CAR therapy utilizing natural killer T cells (CAR-NKT) at the upcoming 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) April 29 - May 2 in Washington, D.C.

Chris Nowers, Cell Medica's CEO, said: "Our next-generation CAR-NKT platform combines the unique natural antitumor properties of NKT cells with innovative CAR constructs, enabling the possibility of producing multiple highly tumor-specific therapeutic products. We believe this approach could open up the broad potential of NKT cells to serve as a basis for off-the-shelf cell therapies targeting both solid and hematological tumors. We look forward to the important new updates that our collaborators at Baylor and Texas Children's Hospital will be sharing at ASGCT."

Details of the three oral presentations:

Harnessing Natural and Engineered Properties of iNKT Cells for Adoptive Cancer Immunotherapy
Presenter: Dr. Leonid Metelitsa, Profess